Literature DB >> 7528184

Intrathecal morphine in the treatment of chronic intractable pain.

F A Chambers1, R MacSullivan.   

Abstract

Fifteen patients with intractable pain received intrathecal morphine delivered via a programmable (Medtronic) device. In twelve patients the pain was due to cancer and three patients had pain of non malignant origin. All of the patients reported excellent or good relief. A total of 14 complications were reported in 7 patients. Most of these were minor and related to surgical or mechanical problems. One patient with pain of non malignant origin developed serious complications which required the removal of the infusion device. The results of this study show that chronic intrathecal infusion of morphine is superior to conventional forms of analgesia in patients with intractable pain of malignant origin. We would advise that it should remain a therapy of last resort in patients with intractable non malignant pain as the long term side effects are still unknown and the potential for serious side effects still exists.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528184     DOI: 10.1007/bf02943074

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  17 in total

1.  Administration of intraspinal morphine sulfate for the treatment of intractable cancer pain.

Authors:  A G Shetter; M N Hadley; E Wilkinson
Journal:  Neurosurgery       Date:  1986-06       Impact factor: 4.654

2.  Epidural versus intrathecal morphine-bupivacaine: assessment of consecutive treatments in advanced cancer pain.

Authors:  P Nitescu; L Appelgren; L E Linder; M Sjöberg; E Hultman; I Curelaru
Journal:  J Pain Symptom Manage       Date:  1990-02       Impact factor: 3.612

3.  Chronic intrathecal morphine for intractable pain.

Authors:  R D Penn; J A Paice
Journal:  J Neurosurg       Date:  1987-08       Impact factor: 5.115

4.  Spinal analgesia with morphine and clonidine.

Authors:  L M Kitahata
Journal:  Anesth Analg       Date:  1989-03       Impact factor: 5.108

5.  Long-term pain relief produced by intrathecal morphine infusion in 53 patients.

Authors:  B M Onofrio; T L Yaksh
Journal:  J Neurosurg       Date:  1990-02       Impact factor: 5.115

6.  Constant infusion of morphine for intractable cancer pain using an implanted pump.

Authors:  S J Hassenbusch; P K Pillay; M Magdinec; K Currie; J W Bay; E C Covington; M Z Tomaszewski
Journal:  J Neurosurg       Date:  1990-09       Impact factor: 5.115

Review 7.  The treatment of cancer pain.

Authors:  K M Foley
Journal:  N Engl J Med       Date:  1985-07-11       Impact factor: 91.245

8.  Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders.

Authors:  E S Krames; J Gershow; A Glassberg; T Kenefick; A Lyons; P Taylor; D Wilkie
Journal:  Cancer       Date:  1985-08-01       Impact factor: 6.860

9.  Analgesia mediated by a direct spinal action of narcotics.

Authors:  T L Yaksh; T A Rudy
Journal:  Science       Date:  1976-06-25       Impact factor: 47.728

10.  Treatment of lower extremity reflex sympathetic dystrophy with continuous intrathecal morphine infusion.

Authors:  R R Goodman; R Brisman
Journal:  Appl Neurophysiol       Date:  1987
View more
  3 in total

Review 1.  Intrathecal analgesia for refractory cancer pain.

Authors:  Scott Newsome; Bridget K Frawley; Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2008-08

2.  Safety and Efficacy of the Use of Intrathecal Morphine for Spinal Three Column Osteotomy.

Authors:  Jason R Audlin; Swamy Kurra; William Lavelle; Richard A Tallarico; Mike H Sun; Nathaniel R Ordway; Elizabeth A Demers Lavelle
Journal:  Cureus       Date:  2017-11-03

3.  MicroRNA-365 alleviates morphine analgesic tolerance via the inactivation of the ERK/CREB signaling pathway by negatively targeting β-arrestin2.

Authors:  Xian-Ping Wu; Rui-Xuan She; Yan-Ping Yang; Zu-Min Xing; Han-Wen Chen; Yi-Wen Zhang
Journal:  J Biomed Sci       Date:  2018-02-07       Impact factor: 8.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.